Compare BRAG & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRAG | RNXT |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 38.8M |
| IPO Year | 2021 | 2021 |
| Metric | BRAG | RNXT |
|---|---|---|
| Price | $1.72 | $0.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.00 | ★ $8.25 |
| AVG Volume (30 Days) | 30.7K | ★ 220.3K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | $6.67 | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $1.42 | $0.70 |
| 52 Week High | $4.75 | $1.45 |
| Indicator | BRAG | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 45.13 |
| Support Level | $1.60 | $0.81 |
| Resistance Level | $1.83 | $1.07 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 14.29 | 28.88 |
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from Malta, and the rest from Netherlands, Curacao, the United States, Croatia, Marshall Islands, Brazil, Isle of Man, Belgium, Czech Republic, and other regions.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.